This work investigates the preparation of Oxytetracycline Hydrochloride loaded alginate beads to take advantage of the swelling properties of alginate beads for improving the oral delivery. Variations in polymer concentration, concentration of cross-linking agent and cross-linking time were examined systemically for their effects on the particle size, entrapment efficiency, percent yield, flow properties and In vitro drug release behavior. Calcium alginate (Ca-alginate) beads of Oxytetracycline hydrochloride were prepared by ionic-gelation method. Shape and surface characteristics were determined by scanning electron microscopy (SEM). Average particle size of drug-loaded beads was determined by sieving method. In vitro drug release behavior from Ca-alginate beads were carried out in simulated gastric fluid (SGF) for first 2 h and simulated intestinal fluid (SIF) for the next 6 h. SEM confirmed spherical shape of beads with rough and porous morphology. The average particle size of the beads was in the range of 470.96 ± 15.22 to 709.33 ± 16.28 µm. Results indicated that the average particle size and flow property of the beads increased with an increase in the concentration of polymer and the cross-linking agent as well as the cross-linking time. The entrapment efficiency and percentage yield was found to be in the range of 52.87 ± 1.56 to 61.76 ± 0.96 % and 69.98 ± 0.33 to 78.94 ± 0.43 % respectively. Concentration of the sodium alginate up to 1.75 % w/v, cross-linker concentration up to 2 % w/v and cross-linking time (30 min) shows highest percent entrapment efficiency (61.76 ± 0.96 %) and % yield (78.94 ± 0.43 %). A decrease in the rate and extent of drug release was observed with relative increase in the polymer concentration, cross- linker concentration and cross-linking time. No significant drug-polymer interaction was observed in DSC study. From this study it can be concluded that the natural polymer sodium alginate can prolong the release of Oxytetracycline Hydrochloride.
There has been a growing interest in the use of natural polymers as drug carriers due to their biocompatibility and biodegradability. Sodium alginate (Na-alginate), is a sodium salt of alginic acid, a naturally occurring polysaccharides obtained from marine brown algae are known to be haemocompatible, nontoxic and do not accumulate in any organ of the body when taken orally 1. Alginate can be considered as block polymers which mainly consist of mannuronic acid (M), guluronic acid (G) and are arranged in homopolymeric blocks (GG and MM) and in heteropolymeric blocks (MG) 2. Sodium alginate is soluble in water and can be cross-linked in the presence of divalent or polyvalent cations such as Ca2+ and Zn2+. The gelation phenomena can be explained by the egg-box model in which divalent cation bind to two carboxyl groups on the adjacent alginate molecules 3, 4. The hydrogel properties of calcium alginate beads have been proposed for controlling the release of small molecules and macromolecules 5.
Oxytetracycline hydrochloride (OTC HCl) is a broad spectrum bacteriostatic antibiotic commonly used for systemic therapy as well as locally for gastric or intestinal infections. It is presently considered as therapy of choice in papulopustulous acne, rosacea and perioral dermatitis as well as primary and secondary skin infections 6. Conventional oral formulations of OTC HCl lead to gastrointestinal irritative effects such as stomach upset, epigastric burning, nausea and vomiting due to high solubility of this drug in the gastric fluid 7. These adverse effects create a potential need to modify its release characteristics. Thus, this study was undertaken to develop prolonged-release formulation of OTC HCl using alginate beads. The development of formulation and characterization of the prepared calcium alginate (Ca-alginate) beads were investigated. Process variables such as polymer concentration, cross-linking agent concentration and cross-linking time were varied. Drug-polymer interaction in the solid state were studied by differential scanning calorimetric analysis (DSC) and the surface characteristics were evaluated by scanning electron microscopy (SEM).
Oxytetracycline hydrochloride (Purity: 95.3 % and Lot No.: Y1-0803192-1) was obtained from Siemens Laboratory, Gurgaon, India. Sodium alginate (M.W.∼147,000 and Lot No. E06Z/0406/2303/13) was purchased from S.D. Fine Chemical Ltd., Mumbai, India. Calcium Chloride was obtained from Qualigens Fine Chemical, Mumbai, India. All other chemicals of analytical grade were purchased from commercial sources.
2.2. MethodsFormulation and schematic illustration of OTC HCl loaded Ca-alginate beads formulations are shown in Table 1. OTC HCl loaded Ca-alginate beads were prepared by using ionic-gelation method 8, 9. Briefly, OTC HCl (2 % w/v) was added to an aqueous solution of sodium alginate and dispersed homogenously. This sodium alginate-drug dispersion was dropped manually through a needle (Size No. 26G) with the help of a hypodermic syringe into a calcium chloride (CaCl2) solution which is used as cross-linking agent. Alginate gel beads were allowed to stand in CaCl2 solution until they were fully formed. The beads were then separated by filtration on filter paper, washed three times with double distilled water and then beads were allowed to dry at room temperature in a desiccator until constant weight was achieved.
The surface morphology of beads was studied by scanning electron microscopy (SEM) (JEOL JSM-1600, Tokyo, Japan) using gold sputter technique. The beads were vacuum dried, coated with gold palladium and observed microscopically. Average particle size of beads was determined by sieving method 10.
The flow property of the beads was determined from the changes in the volume due to rearrangement and packing which occurs during tapping in a graduated measuring cylinder. Carr’s compressibility index (%) and Hausner ratio were determined by using following formula 11:
![]() |
![]() |
Beads were accurately weighed and broken down using mortar and pestle. 10 mg of the crushed beads were taken into 10 ml of volumetric flask and add methanol up-to the mark, vortexed for 5 min and filtered through whatmann filter paper No. 4. The filtered samples were suitably diluted and analyzed for drug content spectrophotometrically (Shimadzu 1700, Japan) at 353 nm 12. The entrapment efficiency was calculated by using the following formula 13:
![]() |
The swelling rate of the Ca-alginate beads were carried out in two aqueous media: 0.1 N HCl (pH 1.2) as simulated gastric fluid (SGF) and phosphate buffer (pH 7.4) as simulated intestinal fluid (SIF). The beads were incubated in solutions at 37°C temperature. The swollen beads were removed at preset time intervals and weighed. The extent of swelling (% swelling) was determined by suspending the beads in 0.1N HCl (pH 1.2) solution at 37°C until equilibrium was achieved. The extent of swelling was determined by calculating the % weight uptake using the following equation 14:
![]() |
Where, Ws is the weight of beads in the swollen state and Wi is the initial weight of the beads.
The In vitro drug release studies were carried out using USP (Type-I) dissolution test apparatus. The capsules filled with drug-loaded beads (equivalent to 250 mg of OTC HCl) were put into the basket. Basket was placed in 900 ml of the dissolution medium at 37±0.5°C and rotated at 75 rpm. The release of drug from beads were monitored in 0.1 N HCl (pH 1.2) as simulated gastric fluid (SGF) for the first 2 h, followed by phosphate buffer (pH 7.4) as simulated intestinal fluid (SIF) for the next 6 h. At specified time intervals, 5 ml samples were withdrawn and immediately replaced with an equal volume of fresh dissolution medium. Samples were suitably diluted and analyzed spectrophotometrically (Shimadzu 1700, Japan) at 353 nm. All the tests were carried out in triplicate.
The differential scanning calorimetry profile of pure drug and physical mixtures of drug and excipients used in the formulations were recorded by Pyris Diamond DSC-4 (Perkins Elmer, Wellesley, MA) in order to assess the compatibility of excipients used in the formulation with the drug. Thermal behavior was studied under normal conditions with perforated and sealed quartz pans and with a nitrogen gas flow of 200 ml/min. The samples were heated at 10°C/min over temperature range of 26-475°C. The reference sample used in all determination was alumina. The spectra obtained were analyzed for incompatibility.
The gelled beads were formed by ionic interaction between the negatively charged carboxyl groups of sodium alginate and the positively charged counter ion such as Ca++. Scanning electron micrograph of a dried OTC HCl loaded Ca-alginate beads showed that the beads have spherical and the rough surface, as well as presence of little porous and dispersion of drug as fine crystalline particles on the surface of beads were also observed (Figure 1 a & Figure 1b). The drug crystals observed on the surface were probably formed as a result of their migration along with water to the surface during drying.
OTC HCl loaded Ca-alginate beads were prepared by varying the concentration of Na alginate in the formulations to investigate the effect of this parameter on the micromeritic properties such as; particle size, % yield and flowability of the beads (Table 2). Percentage yield of formulations F1, F2, F3, F4 and F5 was found to be 69.98 ± 0.33, 71.40 ± 0.52, 77.16 ± 0.51, 78.94 ± 0.43 and 77.95 ± 0.40 % respectively. It is evident that increasing the polymer concentration has resulted in an increase in the percentage yield. This effect can be explained by the fact that as the concentration of Na alginate increases, the quantity of the polymer becomes sufficient to cover OTC HCl particles completely and form beads. The % yield was found to be in the range of 69.98 ± 0.33 to 78.94 ± 0.43 % (Table 2). The % yield decreased with increasing sodium alginate concentration due to higher concentration of Na alginate (more than 1.75 % w/v) resulted in much higher viscosity of solution which resulted in the formation of lumps and hence decreased yields. Analysis of the particle size indicated that the average particle size increased significantly (p<0.05) with increasing the polymer concentration due to subsequent increase in the frequency of collision, resulting in the fusion of semi formed particles and as a consequence an overall increase in the size of the beads. Plot of the average particle size of the beads against the Na-alginate concentration exhibited close to linearity with r2 value = 0.9711 (Figure 2). Other researchers have reported a similar relationship between the polymer concentration and the mean size 15.
Average particle size was found to vary from 639.86 ± 17.85µm (F4), 646.91 ± 15.03 µm (F6) and 649.26 ± 18.52 µm (F7) on varying the cross-linker concentration from 2 %w/v, 5 %w/v, 10 %w/v respectively which indicated that increase in particle size was also observed with increase in the concentration of cross-linker. However, concentration of the cross-linker above 10 % w/v caused formation of irregular lumps due to extensive cross-linking of the guluronic acid unit of sodium alginate. When the cross-linking time was decrease, the average particle size reduced. Variation of the cross-linker concentration and cross-linking time was devoid of a significant change in the percentage yield.
Table 2 summarizes the flowability of OTC HCl loaded Ca-alginate beads exemplified by Carr’s compressibility index 16 and Hausner ratio 17. The flowability of OTC HCl drug was poor but the flowability of alginate beads was excellent. All beads formulation possessed Carr’s compressibility index in the range of 5–15 and HR less than 1.25 suggesting excellent flow properties of all beads formulations unlike cohesive pure drug. However, a slight decrease in Carr’s index and Hausner ratio of the beads was noticed by increasing the polymer concentration, cross-linker concentration and cross-linking time owing to formation of larger particles. As the particle size increases, the cohesivity of the particles decrease and beads formulation exhibited the low inter-particle friction resulting in good flow property.
3.2. Entrapment efficiencyThe entrapment efficiency was found to be in the range of 52.87 ± 1.56 to 61.76 ± 0.96 % (Table 2). The entrapment efficiency increased progressively with increasing sodium alginate concentration. Increase in the Na-alginate concentration resulted in the formation of lager sized beads entrapping greater amount of the drug. This effect might have occurred due to the greater availability of active calcium-binding site in polymeric chains and consequently, the greater degree of cross-linking as the quantity of sodium alginate increased which generate more space for drug encapsulation 2. Concentration of the sodium alginate up to 1.75 % w/v and cross-linker concentration up to 2 % w/v (F4) shows highest percent entrapment efficiency i.e. 61.76 ± 0.96 %. However, further increase in the concentration of sodium alginate and CaCl2 result in decrease in the entrapment efficiency. This could be due to the instant gelling of sodium alginate on addition of calcium chloride and squeezing out of the aqueous phase from the gel lattice which caused OTC HCl comes out from gel lattice along with squeezed aqueous phase. Variation in cross-linking time were also studied, entrapment efficiency decreases as the cross-link time decreases. Cross-linking time of 30 min was found to be optimum as it yielded highest entrapment efficiency; less cross-linking time resulted in incomplete gelling of sodium alginate 18.
The swelling behavior of alginate polymer is the major factor for controlling the drug release from the beads system. The percentage water uptake of OTC HCl loaded Ca-alginate beads was determined in 0.1 N HCl (pH 1.2) and phosphate buffer (pH 7.4) 19. As shown in Figure 3, the beads exhibited highest water uptake in phosphate buffer (pH 7.4), while lowest water uptake was noticed in 0.1 N HCl (pH 1.2). Maximum water uptake was obtained at 2-3 hours in phosphate buffer pH 7.4, subsequently erosion and breakdown occurred. These results suggested that the dried beads will swell slightly in stomach and they are subsequently transferred to upper intestine, where the beads begin to swell more and behave as matrices for controlled release of loaded drug.
The extent of swelling (% swelling) of the bead was determined in 0.1 N HCl (pH 1.2) by using different concentration of sodium alginate polymer. The results showed that swelling was related to the polymer concentration, more swelling was found for beads containing high polymer concentration (Figure 4). This effect may occur due to increase in beads volume as the concentration of sodium alginate increased 20.
To study the effect of sodium alginate on OTC HCl release, sodium alginate was used at five different concentrations: 1.0 (F1), 1.25 (F2), 1.50 (F3),1.75 (F4) and 2.0 (F5) %w/v. In vitro drug release study shows that the release of drug from F1 formulation was found to be 67.96 ± 2.52 % at pH 1.2 within 2 h. After 2 h, the calcium alginate beads (F1) disintegrated and lost remaining drug within 3 h in dissolution medium SIF (pH 7.4). Figure 5 indicate that with increase in concentration of sodium alginate (F2, F3, F4, and F5), the release of entrapped drug during first 2 h in SGF was significantly reduced and more sustained the drug release. The release of OTC HCl from F2, F3, F4 and F5 formulations was found to 68.36 ± 1.82, 67.24 ± 2.44, 48.22 ± 1.46 and 46.82 ± 1.38 % respectively at pH 1.2 within 2 h but after 2 h, only F4 and F5 followed the drug release pattern extending up to 8 h. A decrease in the rate and extent of release was observed with relative increase in the polymer concentration in beads, can be attributed by the increase in the extent of swelling and gel layer thickness that acted as a barrier for penetration of dissolution medium within polymer matrix thereby retarding the diffusion of OTC HCl from swollen alginate matrix 21. The effect of cross-linker concentration on drug release was shown in Figure 6. The result shows that the release of OTC HCl from the beads decreased with increased cross-linking agent concentration. However, except for 2 % w/v CaCl2 (F4), the drug release from F7 formulation (5 % w/v CaCl2) and F7 formulation (10 % w/v CaCl2 ) did not vary significantly (p>0.5). OTC HCl release from beads was also decrease and more sustained with increasing the cross-linking time, F8 and F9 caused no significant change (p >0.5) in the amount of drug release (Figure 7). This could be observed due to the increasing cross-linking density that hindering drug release from beads.
Thermal behavior of Oxytetracycline hydrochloride and physical mixture with polymer (Na-alginate) was investigated by DSC. Figure 8 Shows the DSC thermo grams obtained during the heating stage for Oxytetracycline hydrochloride (A), sodium alginate (B), Oxytetracycline hydrochloride: sodium alginate mixture (C). The DSC thermogram of Oxytetracycline hydrochloride (A) showed one endothermic peak at 61C and two exothermic peaks at 195C and 214C. The DSC curve for physical mixtures of Oxytetracycline hydrochloride and sodium alginate (D) exhibited one endothermic peak at 62C and two exothermic peaks at 194C and 231C. The exothermic peak at 231C which show the peak of sodium alginate (Figure 8, B). This clearly showed that there were no changes in the DSC thermogram of pure drug in presence of Na-alginate, indicating absence of interactions between the drug and polymer.
In this study, Ca-alginate beads of Oxytetracycline Hydrochloride were prepared by using ionic-gelation method. The ability of calcium alginate beads to incorporate the OTC HCl and prolonged release of Oxytetracycline Hydrochloride has been investigated through variation in processing conditions. Variables such as polymer concentration, cross-linking agent concentration and cross-linking time were considered. Drug release and entrapment efficiency were affected by polymer concentration, cross-linking agent concentration and cross-linking time. From this study it can be concluded that a natural polymer sodium alginate can be used to prolong the release of Oxytetracycline Hydrochloride. DSC study did not reveal any significant drug interactions.
The authors are grateful to IIT, Roorkee, India for carrying out SEM and DSC analysis and also thankful to Siemens Laboratory, Gurgaon, India for providing gift sample of Oxytetracycline hydrochloride.
The authors declare no conflict of interest
[1] | Kim CK, Lee EJ. The controlled release of blue dextran from alginate beads. Int J Pharm 1992; 79: 11-19. | ||
In article | View Article | ||
[2] | El-Kamal AH, Al-Gohary OM, Hosny EA. Alginate-diltiazem hydrochloride beads: optimization of formulation factors, in vitro and in vivo availability. J Microencapsul 2003; 20: 211-225. | ||
In article | View Article | ||
[3] | Heng P, Chan L, Wong T. Formation of alginate microspheres produced using emulsification technique. J Microencapsul 2003; 20: 401-413. | ||
In article | View Article PubMed | ||
[4] | George M, Abraham TE. Poly-ionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan- A review. J Control Rel 2006; 114: 1-14. | ||
In article | View Article PubMed | ||
[5] | Gombotz W, Wee S. Protein release from alginate matrices. Adv Drug Deliv Rev 1998;31: 267-285. | ||
In article | View Article | ||
[6] | Olszewska M. Oxytetracycline mechanism of action and application in skin diseases. Wiad Lek 2006; 59: 829-833. | ||
In article | PubMed | ||
[7] | Sweetman SC. Martindale: The complete drug reference. 33rd ed. The Pharmaceutical Press 2002; 258-260. | ||
In article | |||
[8] | Rodriguez MLG, Holgado MA, Lafuente CS, Rabasco AM, Fini A. Alginate/chitosan particulate systems for sodium diclofenac release. Int J Pharm 2002; 232: 225-234. | ||
In article | View Article | ||
[9] | Takeshita S, Sugawara S, Imai T, Otagiri M. Preparation and evaluation of controlled release formulation of nefedepine using alginate beads. Biol Pharm Bull 1993; 16: 420-424. | ||
In article | View Article | ||
[10] | Mishra B, Jayanth P, Sankar C. Development of chitosan-alginate microcapsules for colon specific delivery of metronidazole. Indian Drugs 2003; 40: 695-700. | ||
In article | |||
[11] | Aulton ME. Pharmaceutics: The science of dosage form design. 2nd ed. Churchill Livingston, New York 2002; 197-210. | ||
In article | |||
[12] | Vijaya DR, Razzak M, Tucker IG, Medlicott NJ. Encapsulation of vitamin B12 into polylactide (ε-caprolactone) microparticles using w-o-w emulsion system. Indian Drugs 2006; 43: 457-461. | ||
In article | |||
[13] | Soppimath K, Kulkarni A, Aminabhavi T. Encapsulation of antihypertensive drugs in cellulose-based matrix microspheres: characterization and release kinetics of microspheres and tableted microspheres. J Microencapsul 2001; 18: 397-409. | ||
In article | View Article PubMed | ||
[14] | El-Gibaly I. Oral delayed-release system based on Zn-pectinate gel (ZPG) microparticles as an alternative carrier to calcium pectinate beads for colonic drug delivery. Int J Pharm 2002; 232: 199-211. | ||
In article | View Article | ||
[15] | Arica B, Calis S, Atilla P, Durlu N, Cakar N, Kas H, Hincal A. In vitro and in vivo studies of ibuprofen-loaded biodegradable alginate beads. J Microencapsul 2005; 22: 153-165. | ||
In article | View Article PubMed | ||
[16] | Carr R. Evaluating flow properties of solids. Chem Eng 1965; 18: 163-168. | ||
In article | View Article | ||
[17] | Hausner H. Friction conditions in a mass metal powder. Int J Powder Metall 1967; 3: 7-13. | ||
In article | View Article | ||
[18] | Rastogi R, Sultana Y, Aqil M, Ali A, Kumar S, Chuttani K, Mishra AK. Alginate microspheres of isoniazid for oral sustained drug delivery. Int J Pharm 2007; 334: 71-77. | ||
In article | View Article PubMed | ||
[19] | Lin S, Ayres J. Calcium alginate beads as core carriers of 5-aminosalisylic acid. Pharm Res 1992; 9: 1128-1131. | ||
In article | View Article PubMed | ||
[20] | Gaudio P, Colombo P, Colombo G, Russo P, Sonvico F. Mechanisms of formation and disintegration of alginate beads obtained by prilling. Int J Pharm 2005; 302: 1-9. | ||
In article | View Article PubMed | ||
[21] | Al-Kassaa RS, Al-Gohary OMN, Al-Faadhel MM. Controlling of systematic absorption of gliclazide through incorporation into alginate beads. Int J Pharm 2007; 341: 230-237. | ||
In article | View Article PubMed | ||
Published with license by Science and Education Publishing, Copyright © 2017 Lalit Kumar Tyagi, Ravi Shekhar, Kalpesh Gaur and Mohan Lal Kori
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit
https://creativecommons.org/licenses/by/4.0/
[1] | Kim CK, Lee EJ. The controlled release of blue dextran from alginate beads. Int J Pharm 1992; 79: 11-19. | ||
In article | View Article | ||
[2] | El-Kamal AH, Al-Gohary OM, Hosny EA. Alginate-diltiazem hydrochloride beads: optimization of formulation factors, in vitro and in vivo availability. J Microencapsul 2003; 20: 211-225. | ||
In article | View Article | ||
[3] | Heng P, Chan L, Wong T. Formation of alginate microspheres produced using emulsification technique. J Microencapsul 2003; 20: 401-413. | ||
In article | View Article PubMed | ||
[4] | George M, Abraham TE. Poly-ionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan- A review. J Control Rel 2006; 114: 1-14. | ||
In article | View Article PubMed | ||
[5] | Gombotz W, Wee S. Protein release from alginate matrices. Adv Drug Deliv Rev 1998;31: 267-285. | ||
In article | View Article | ||
[6] | Olszewska M. Oxytetracycline mechanism of action and application in skin diseases. Wiad Lek 2006; 59: 829-833. | ||
In article | PubMed | ||
[7] | Sweetman SC. Martindale: The complete drug reference. 33rd ed. The Pharmaceutical Press 2002; 258-260. | ||
In article | |||
[8] | Rodriguez MLG, Holgado MA, Lafuente CS, Rabasco AM, Fini A. Alginate/chitosan particulate systems for sodium diclofenac release. Int J Pharm 2002; 232: 225-234. | ||
In article | View Article | ||
[9] | Takeshita S, Sugawara S, Imai T, Otagiri M. Preparation and evaluation of controlled release formulation of nefedepine using alginate beads. Biol Pharm Bull 1993; 16: 420-424. | ||
In article | View Article | ||
[10] | Mishra B, Jayanth P, Sankar C. Development of chitosan-alginate microcapsules for colon specific delivery of metronidazole. Indian Drugs 2003; 40: 695-700. | ||
In article | |||
[11] | Aulton ME. Pharmaceutics: The science of dosage form design. 2nd ed. Churchill Livingston, New York 2002; 197-210. | ||
In article | |||
[12] | Vijaya DR, Razzak M, Tucker IG, Medlicott NJ. Encapsulation of vitamin B12 into polylactide (ε-caprolactone) microparticles using w-o-w emulsion system. Indian Drugs 2006; 43: 457-461. | ||
In article | |||
[13] | Soppimath K, Kulkarni A, Aminabhavi T. Encapsulation of antihypertensive drugs in cellulose-based matrix microspheres: characterization and release kinetics of microspheres and tableted microspheres. J Microencapsul 2001; 18: 397-409. | ||
In article | View Article PubMed | ||
[14] | El-Gibaly I. Oral delayed-release system based on Zn-pectinate gel (ZPG) microparticles as an alternative carrier to calcium pectinate beads for colonic drug delivery. Int J Pharm 2002; 232: 199-211. | ||
In article | View Article | ||
[15] | Arica B, Calis S, Atilla P, Durlu N, Cakar N, Kas H, Hincal A. In vitro and in vivo studies of ibuprofen-loaded biodegradable alginate beads. J Microencapsul 2005; 22: 153-165. | ||
In article | View Article PubMed | ||
[16] | Carr R. Evaluating flow properties of solids. Chem Eng 1965; 18: 163-168. | ||
In article | View Article | ||
[17] | Hausner H. Friction conditions in a mass metal powder. Int J Powder Metall 1967; 3: 7-13. | ||
In article | View Article | ||
[18] | Rastogi R, Sultana Y, Aqil M, Ali A, Kumar S, Chuttani K, Mishra AK. Alginate microspheres of isoniazid for oral sustained drug delivery. Int J Pharm 2007; 334: 71-77. | ||
In article | View Article PubMed | ||
[19] | Lin S, Ayres J. Calcium alginate beads as core carriers of 5-aminosalisylic acid. Pharm Res 1992; 9: 1128-1131. | ||
In article | View Article PubMed | ||
[20] | Gaudio P, Colombo P, Colombo G, Russo P, Sonvico F. Mechanisms of formation and disintegration of alginate beads obtained by prilling. Int J Pharm 2005; 302: 1-9. | ||
In article | View Article PubMed | ||
[21] | Al-Kassaa RS, Al-Gohary OMN, Al-Faadhel MM. Controlling of systematic absorption of gliclazide through incorporation into alginate beads. Int J Pharm 2007; 341: 230-237. | ||
In article | View Article PubMed | ||